计算溶液所需的质量、体积或浓度。
活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
---|
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
S127746-1mg |
1mg |
现货 ![]() |
| |
S127746-5mg |
5mg |
现货 ![]() |
| |
S127746-25mg |
25mg |
现货 ![]() |
| |
S127746-100mg |
100mg |
期货 ![]() |
|
英文别名 | A832881 | A14092 | AKOS000272680 | EX-A623 | HY-14339 | 3-benzenesulfonyl-8-piperazin-1-ylquinoline | 3-(benzenesulfonyl)-8-(1-piperazinyl)quinoline | J-510926 | Intepirdine [USAN] | SB 742457 | [4-[4-(4-Hydroxyphenyl)-1-piperazinyl]phenyl]carbamic acid p |
---|---|
规格或纯度 | Moligand™, ≥97% |
英文名称 | SB742457 |
生化机理 | SB-742457是一种5-HT6受体拮抗剂,它在阿尔茨海默病(AD)患者中的应用进一步彰显了这种机理方法的治疗前景。阿尔茨海默病是一种破坏性神经疾病,其特征是认知能力逐渐下降,并伴有行为和心理综合征,如抑郁和精神病。随着选择性 5-HT6 受体拮抗剂的开发,啮齿类动物和灵长类动物的临床前研究更详细地阐明了这种受体亚型的功能。越来越清楚的是,阻断 5-HT6 受体可改善各种学习和记忆范例中的认知能力,还可产生抗焦虑和抗抑郁类似活性。SB-742457 一般安全且耐受性良好,可能对阿尔茨海默病有效。对其他受体的选择性超过 100 倍。可逆转动物模型的学习障碍。 |
储存温度 | -20°C储存 |
运输条件 | 超低温冰袋运输 |
作用类型 | 拮抗剂 |
作用机制 | 羟色胺 6(5-HT6)受体拮抗剂 |
备注 | 如果有可能,您尽量在使用的当天配置溶液,并在当天使用完它。但是,如果您需要预先配制储备溶液,我们建议您将溶液等份保存在-20°C的密封小瓶中。通常,它们最多可以使用一个月。在使用前和打开样品瓶之前,我们建议您让您的产品在室温下平衡至少1小时。有毒,请参阅SDS以获取更多信息。需要更多关于溶解度,用法和处理的建议吗?请访问我们的常见问题(FAQ)页面以获取更多详细信息。 |
产品介绍 |
SB742457 (GSK 742457) is a highly selective 5-HT6 receptor antagonist with pKi of 9.63, exhibits >100-fold selectivity over other receptors. Phase 2. SB742457 (GSK 742457) is a highly selective 5-HT6 receptor antagonist with pKi of 9.63, exhibits >100-fold selectivity over other receptors. Phase 2. |
ALogP | 2.5 |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
---|
PubChem SID | 504766218 |
---|---|
分子类型 | 小分子 |
IUPAC Name | 3-(benzenesulfonyl)-8-piperazin-1-ylquinoline |
INCHI | InChI=1S/C19H19N3O2S/c23-25(24,16-6-2-1-3-7-16)17-13-15-5-4-8-18(19(15)21-14-17)22-11-9-20-10-12-22/h1-8,13-14,20H,9-12H2 |
InChi Key | JJZFWROHYSMCMU-UHFFFAOYSA-N |
Canonical SMILES | C1CN(CCN1)C2=CC=CC3=CC(=CN=C32)S(=O)(=O)C4=CC=CC=C4 |
Isomeric SMILES | C1CN(CCN1)C2=CC=CC3=CC(=CN=C32)S(=O)(=O)C4=CC=CC=C4 |
PubChem CID | 11256720 |
分子量 | 353.44 |
溶解性 | DMSO 78 mg/mL Water <1 mg/mL Ethanol 2 mg/mL |
---|---|
分子量 | 353.400 g/mol |
XLogP3 | 2.500 |
氢键供体数Hydrogen Bond Donor Count | 1 |
氢键受体数Hydrogen Bond Acceptor Count | 5 |
可旋转键计数Rotatable Bond Count | 3 |
精确质量Exact Mass | 353.12 Da |
单同位素质量Monoisotopic Mass | 353.12 Da |
拓扑极表面积Topological Polar Surface Area | 70.700 Ų |
重原子数Heavy Atom Count | 25 |
形式电荷Formal Charge | 0 |
复杂度Complexity | 535.000 |
同位素原子数Isotope Atom Count | 0 |
定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
所有立体化学键的总数The total count of all stereochemical bonds | 0 |
共价键合单元计数Covalently-Bonded Unit Count | 1 |
象形图 | GHS06 |
---|---|
信号词 | Danger |
危险声明 |
H301: 吞咽会中毒 |
预防措施声明 |
P321: 特殊处理(请参阅此标签上的...)。 P405: 密闭存放 P501: 将内容物/容器处理到。。。 P264: 处理后要彻底洗手。 P270: 使用本产品时,请勿进食、饮水或吸烟。 P330: 漱口 P301+P316: 如果吞咽:立即寻求紧急医疗救助。 |
1. Liu KG, Lo JR, Comery TA, Zhang GM, Zhang JY, Kowal DM, Smith DL, Di L, Kerns EH, Schechter LE et al.. (2009) Identification of a novel series of 3-piperidinyl-5-sulfonylindazoles as potent 5-HT6 ligands.. Bioorg Med Chem Lett, 19 (12): (3214-6). [PMID:19433358] [10.1021/op500134e] |
2. Maher-Edwards G, Zvartau-Hind M, Hunter AJ, Gold M, Hopton G, Jacobs G, Davy M, Williams P. (2010) Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease.. Curr Alzheimer Res, 7 (5): (374-85). [PMID:20043816] [10.1021/op500134e] |
3. Maher-Edwards G, Dixon R, Hunter J, Gold M, Hopton G, Jacobs G, Hunter J, Williams P. (2011) SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study.. Int J Geriatr Psychiatry, 26 (5): (536-44). [PMID:20872778] [10.1021/op500134e] |
4. Callaghan CK, Hok V, Della-Chiesa A, Virley DJ, Upton N, O'Mara SM. (2012) Age-related declines in delayed non-match-to-sample performance (DNMS) are reversed by the novel 5HT6 receptor antagonist SB742457.. Neuropharmacology, 63 (5): (890-7). [PMID:22766392] [10.1021/op500134e] |
5. Ferrero H, Solas M, Francis PT, Ramirez MJ. (2017) Serotonin 5-HT6 Receptor Antagonists in Alzheimer's Disease: Therapeutic Rationale and Current Development Status.. CNS Drugs, 31 (1): (19-32). [PMID:27914038] [10.1021/op500134e] |
6. Rossé G, Schaffhauser H. (2010) 5-HT6 receptor antagonists as potential therapeutics for cognitive impairment.. Curr Top Med Chem, 10 (2): (207-21). [PMID:20166958] [10.1021/op500134e] |